Discovery of molidustat (BAY 85-3934): A small-molecule oral HIF-prolyl hydroxylase (HIF-PH) inhibitor for the treatment of renal anemia

被引：0

作者：

Beck, Hartmut ^{[1
]}

机构：

[1] Bayer AG, Pharmaceut, Wuppertal, Germany

来源：

ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 2017年 / 254卷

关键词：

D O I：

暂无

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

247

引用

页数：1

共 17 条

[1] Discovery of Molidustat (BAY85-3934): A Small-Molecule Oral HIF-Prolyl Hydroxylase (HIF-PH) Inhibitor for the Treatment of Renal Anemia
Beck, Hartmut
Jeske, Mario
Thede, Kai
Stoll, Friederike
Flamme, Ingo
Akbaba, Metin
Ergueden, Jens-Kerim
Karig, Gunter
Keldenich, Joerg
Oehme, Felix
Militzer, Hans-Christian
Hartung, Ingo V.
Thuss, Uwe
[J]. CHEMMEDCHEM, 2018, 13 (10) : 988 - 1003
[2] First-in-man-proof of concept study with molidustat: a novel selective oral HIF-prolyl hydroxylase inhibitor for the treatment of renal anaemia
Boettcher, M.
Lentini, S.
Arens, E. R.
Kaiser, A.
van der Mey, D.
Thuss, U.
Kubitza, D.
Wensing, G.
[J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 84 (07) : 1557 - 1565
[3] IRON REGULATION BY MOLIDUSTAT, BAY 85-3934, A DAILY ORAL HYPOXIA-INDUCIBLE FACTOR PROLYL HYDROXYLASE INHIBITOR IN PATIENTS WITH CHRONIC KIDNEY DISEASE
Akizawa, Tadao
Macdougall, Iain C.
Berns, Jeffrey S.
Bernhardt, Thomas
Taguchi, Megumi
Ogura, Eriko
Lekushi, Kazuma
[J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2018, 33
[4] Mimicking Hypoxia to Treat Anemia: HIF-Stabilizer BAY 85-3934 (Molidustat) Stimulates Erythropoietin Production without Hypertensive Effects
Flamme, Ingo
Oehme, Felix
Ellinghaus, Peter
Jeske, Mario
Keldenich, Joerg
Thuss, Uwe
[J]. PLOS ONE, 2014, 9 (11):
[5] Discovery of JTZ-951: A HIF Prolyl Hydroxylase Inhibitor for the Treatment of Renal Anemia
Ogoshi, Yosuke
Matsui, Takuya
Mitani, Ikuo
Yokota, Masahiro
Terashita, Masakazu
Motoda, Dai
Ueyama, Kazuhito
Hotta, Takahiro
Ito, Takashi
Hase, Yasunori
Fukui, Kenji
Deai, Katsuya
Yoshiuchi, Hiromi
Ito, Soichiro
Abe, Hiroyuki
[J]. ACS MEDICINAL CHEMISTRY LETTERS, 2017, 8 (12): : 1320 - 1325
[6] Effects of oral iron and calcium supplement on the pharmacokinetics and pharmacodynamics of molidustat: an oral HIF-PH inhibitor for the treatment of renal anaemia
Lentini, Silvia
Kaiser, Andreas
Kapsa, Stefanie
Matsuno, Kumi
van der Mey, Dorina
[J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 76 (02) : 185 - 197
[7] The HIF-PHI BAY 85-3934 (Molidustat) Improves Anemia and Is Associated With Reduced Levels of Circulating FGF23 in a CKD Mouse Model
Noonan, Megan L.
Ni, Pu
Agoro, Rafiou
Sacks, Spencer A.
Swallow, Elizabeth A.
Wheeler, Jonathan A.
Clinkenbeard, Erica L.
Capitano, Maegan L.
Prideaux, Matthew
Atkins, Gerald J.
Thompson, William R.
Allen, Matthew R.
Broxmeyer, Hal E.
White, Kenneth E.
[J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2021, 36 (06) : 1117 - 1130
[8] Effects of oral iron and calcium supplement on the pharmacokinetics and pharmacodynamics of molidustat: an oral HIF–PH inhibitor for the treatment of renal anaemia
Silvia Lentini
Andreas Kaiser
Stefanie Kapsa
Kumi Matsuno
Dorina van der Mey
[J]. European Journal of Clinical Pharmacology, 2020, 76 : 185 - 197
[9] Small-molecule inhibitors of HIF-PHD2: a valid strategy to renal anemia treatment in clinical therapy
Wu, Yue
Wang, Nan
Lei, Yonghua
Hu, Tianhan
You, Qidong
Zhang, Xiaojin
[J]. MEDCHEMCOMM, 2016, 7 (07) : 1271 - 1284
[10] Discovery of DS-1093a: An oral hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of renal anemia
Tanaka, Naoki
Fukuda, Takeshi
Takano, Rieko
Sasaki, Koji
Tsuji, Takashi
Goto, Riki
Kuribayashi, Takeshi
Yamaguchi, Kyoji
Niitsu, Yoichi
Ishii, Ken
Hashimoto, Masami
Takahashi, Shinichi
Obayashi, Hisakuni
[J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2024, 111

← 1 2 →